AHNAK2 (AHNAK Nucleoprotein 2)

These proteins exhibited high-affinity interactions with zavegepant (a clinically approved CGRP receptor antagonist), omilancor, bemcentinib, conivaptan, and APTO-253...Thus, we suggest a systems-level platform for nominating ligandable PDAC targets and clinically actionable compounds. The framework highlights opportunities for rational drug repurposing and motivates future mechanistic studies at the intersection of proteomics and structure-based screening for targets to PDAC.

Furthermore, the top 1% genes with highest iQ(G) scores for each cancer were submitted for KEGG pathway analysis. The results revealed that several genes of the CACNA1 family within the type II diabetes mellitus pathway are likely related to both OvCa and ThCa and suggested other molecular interactions that should be further studied in connection with OvCa prognosis and ThCa treatment.

Patients with AHNAK2-mutated UPLC had significantly shorter overall survival, elevated tumor mutational burden (TMB), and markedly reduced infiltration of CD4⁺, CD8⁺, CD20⁺, and CD68⁺ immune cells. These findings support the recognition of UPLC as a clinically aggressive and molecularly distinct entity and indicate that the AHNAK2 mutation may serve as a potential prognostic biomarker in this rare malignancy.

Additionally, copy number variations (CNVs) were evaluated, identifying chromosomal losses (e.g., Y chromosome, 1p12, 9p21.2-p21.3) and gains (e.g., 1q21.3, 6p22.3). This study establishes a foundational dataset for Bangladeshi bladder cancer patients, paving the way for further validation experiments in vitro, and the possibility of developing population-specific molecular biomarker panels, these insights may also contribute to personalized treatment strategies and help combat rising morbidity and recurrence rates of bladder cancer in Bangladesh.

Exploratory drug-response modeling with pRRophetic suggested lower estimated half-maximal inhibitory concentration (IC50) values for agents including MS-275 (entinostat), PF-4708671, and roscovitine in the high-risk group. The TIDE algorithm carries prognostic information in NSCLC beyond immunotherapy settings. The proposed TIDE-informed gene signature reproduced prognostic stratification across cohorts, suggesting potential applicability to a broader NSCLC population and supporting future personalized risk stratification.

AHNAK2 may serve as a new prognostic biomarker and a prospective therapeutic target in GC.

Our workflow for live CTC capture and sequencing enables discovery of new markers for both epithelial and mesenchymal CTCs. When combined with existing markers, we improve live CTC capture for more holistic studies of the metastatic process and offer a scalable method for discovering CTC markers.

AHNAK2 demonstrates moderate sensitivity and high specificity in the pathological diagnosis of GBC, particularly for well-differentiated ACs. Combining AHNAK2 with IMP3 significantly enhances diagnostic sensitivity, achieving up to 90% across all AC grades.

This study shows that while PMMC has similarities with other melanomas, it also harbors unique mutant genes. These findings provide a basis for exploring PMMC-related molecular markers and developing personalized diagnosis and treatment plans for patients with PMMC.

Furthermore, by applying RNAseq in a standardized workflow, the approach enables both patient-specific and population-level vaccine design, based on statistically frequent gene variants observed across tumor datasets. AutoEpiCollect 2.0 is freely available as a website based tool for user to design vaccine.

Drug susceptibility analysis further demonstrates that AHNAK2 confers significant resistance to bafetinib (r = -0.38, P < .05) and curcumin (r = -0.55, P < .05)...The findings underscore the potential of AHNAK2 to serve as a valuable biomarker for immunotherapy in PAAD. This discovery paves the way for the development of more tailored and efficacious treatment approaches, offering new prospects for improving patient outcomes and advancing the field of PAAD management.

Our findings indicated that the rondom froest model based on five autoantibodies might help identify preclinical and early-stage PC.